Cargando…
Responder analyses for anti-amyloid immunotherapies for Alzheimer’s disease: a paradigm shift by regulatory authorities is urgently needed
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612473/ https://www.ncbi.nlm.nih.gov/pubmed/37901042 http://dx.doi.org/10.1093/braincomms/fcad276 |
| _version_ | 1785128708819910656 |
|---|---|
| author | Salemme, Simone Ancidoni, Antonio Vanacore, Nicola |
| author_facet | Salemme, Simone Ancidoni, Antonio Vanacore, Nicola |
| author_sort | Salemme, Simone |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10612473 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106124732023-10-29 Responder analyses for anti-amyloid immunotherapies for Alzheimer’s disease: a paradigm shift by regulatory authorities is urgently needed Salemme, Simone Ancidoni, Antonio Vanacore, Nicola Brain Commun Letter to the Editor Oxford University Press 2023-10-24 /pmc/articles/PMC10612473/ /pubmed/37901042 http://dx.doi.org/10.1093/braincomms/fcad276 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Salemme, Simone Ancidoni, Antonio Vanacore, Nicola Responder analyses for anti-amyloid immunotherapies for Alzheimer’s disease: a paradigm shift by regulatory authorities is urgently needed |
| title | Responder analyses for anti-amyloid immunotherapies for Alzheimer’s disease: a paradigm shift by regulatory authorities is urgently needed |
| title_full | Responder analyses for anti-amyloid immunotherapies for Alzheimer’s disease: a paradigm shift by regulatory authorities is urgently needed |
| title_fullStr | Responder analyses for anti-amyloid immunotherapies for Alzheimer’s disease: a paradigm shift by regulatory authorities is urgently needed |
| title_full_unstemmed | Responder analyses for anti-amyloid immunotherapies for Alzheimer’s disease: a paradigm shift by regulatory authorities is urgently needed |
| title_short | Responder analyses for anti-amyloid immunotherapies for Alzheimer’s disease: a paradigm shift by regulatory authorities is urgently needed |
| title_sort | responder analyses for anti-amyloid immunotherapies for alzheimer’s disease: a paradigm shift by regulatory authorities is urgently needed |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612473/ https://www.ncbi.nlm.nih.gov/pubmed/37901042 http://dx.doi.org/10.1093/braincomms/fcad276 |
| work_keys_str_mv | AT salemmesimone responderanalysesforantiamyloidimmunotherapiesforalzheimersdiseaseaparadigmshiftbyregulatoryauthoritiesisurgentlyneeded AT ancidoniantonio responderanalysesforantiamyloidimmunotherapiesforalzheimersdiseaseaparadigmshiftbyregulatoryauthoritiesisurgentlyneeded AT vanacorenicola responderanalysesforantiamyloidimmunotherapiesforalzheimersdiseaseaparadigmshiftbyregulatoryauthoritiesisurgentlyneeded |